Anxiety Management in Primary Care: What the Evidence Shows About SSRIs, CBT, and Combination Therapy
Synthesis of 12 studies — including landmark RCTs, 3 major meta-analyses, and network meta-analyses — evaluating first-line treatments for generalized anxiety and panic disorder in adult primary care. Moderate-to-strong evidence base, through 2025.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- Strong evidence supports both SSRIs and CBT as effective first-line anxiety management strategies in primary care, with effect sizes of 0.5–1.0 (Hedges’ g) across GAD, panic disorder, and social anxiety — and combination therapy likely offering the most robust acute response.
- A 2023 network meta-analysis of 65 RCTs (n = 5048) found that only CBT demonstrated sustained long-term effectiveness for GAD after treatment withdrawal, while pharmacotherapy effects tend to diminish upon discontinuation.
- Meta-analytic data indicate that approximately 36% of anxiety patients relapse within one year of stopping antidepressants, compared with a 14% relapse rate following successful CBT — supporting the durability advantage of psychological intervention.
- Critical evidence gaps persist, including insufficient primary care–specific RCTs comparing combination therapy to monotherapy, limited data on sequencing strategies, and a near-complete absence of trials examining CBT-based relapse prevention after SSRI discontinuation in anxiety populations.
Why Anxiety Management in Primary Care Matters
Anxiety disorders affect an estimated 301 million people worldwide and represent the most common mental health conditions encountered in family medicine. In primary care settings, generalized anxiety disorder (GAD) and panic disorder account for the majority of anxiety-related presentations, with prevalence rates of 5–8% in routine clinical populations. Despite effective treatments being available, fewer than half of affected individuals receive adequate therapy, and fewer still receive evidence-based first-line intervention.
The treatment selection dilemma is particularly acute in primary care, where clinician time constraints, limited access to trained CBT therapists, patient preferences, and comorbid depression all shape real-world decision-making. While guidelines from the APA, NICE, and CANMAT consistently recommend both SSRIs and CBT as first-line options, they provide less clarity on when to combine treatments, how to sequence them, and which patients are most likely to benefit from each approach. This synthesis examines the comparative evidence to help clinicians navigate these decisions.
What Evidence Was Reviewed
This synthesis draws on 12 key studies spanning landmark RCTs, large-scale unified meta-analyses, network meta-analyses, and relapse prevention trials. The evidence base covers adult populations with GAD, panic disorder, and social anxiety disorder, with particular attention to studies relevant to primary care contexts.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| Cuijpers 2025 (JAMA Psychiatry) | Unified series of MAs | 32968 | Adults with mental disorders (375 RCTs) | CBT effect sizes for anxiety: g = 0.5–1.0 vs controls; larger effects at follow-up than pharmacotherapy | High |
| Papola 2023 (JAMA Psychiatry) | NMA of 65 RCTs | 5048 | Adults with GAD | Only CBT showed long-term effectiveness after treatment withdrawal; superior to TAU | High |
| Hofmann 2025 | MA of 49 RCTs | 3645 | Adults with anxiety disorders | Mean CBT effect size g = 0.51 (95% CI 0.40–0.62); no decline over 30 years of trials | High |
| Cuijpers 2023 (Depression MA) | MA of 409 RCTs | 52702 | Adults with depression (anxiety overlap) | CBT superior to pharmacotherapy at 6–12 mo follow-up (g = 0.34, 95% CI 0.09–0.58) | High |
| Batelaan 2017 (BMJ) | MA of 28 RCTs | 5233 | Anxiety responders to antidepressants | 36.4% relapse after discontinuation vs 16.4% continuing; OR 3.11 (95% CI 2.48–3.89) | High |
| Lorimer 2021 (CBT relapse MA) | MA of 17 studies | 337 | Remitted anxiety after CBT | 14% overall relapse rate after CBT remission | Moderate |
| Johnco 2025 | SR/MA of 22 RCTs | 2549 | Older adults (≥60) with anxiety | CBT remission 54% vs 36% for pharmacotherapy; CBT attrition 19% | High |
| CANMAT Guidelines 2014/2023 | Clinical practice guideline | NR | Adults with anxiety disorders | SSRIs/SNRIs + pregabalin first-line; CBT recommended as first-line or adjunct | High |
| AAFP Review (Penning 2022) | Clinical review | NR | Adults with GAD/PD in primary care | CBT as effective as pharmacotherapy for PD; combination likely most effective | Moderate |
| Scholten 2018 (CBT + AD discontinuation) | RCT | 87 | Remitted anxiety discontinuing ADs | CBT relapse prevention did not reduce relapse vs discontinuation alone (67% vs 65%) | Moderate |
| White 2013 (Maintenance CBT) | RCT | NR | Remitted anxiety post-AD discontinuation | Maintenance CBT relapse 5.2% vs 18.4% assessment-only at 21 months | Moderate |
| Lancet Psychiatry NMA 2026 (Deprescribing) | NMA of 76 RCTs | 17379 | Adults discontinuing antidepressants | Slow tapering + psychological support: RR 0.52 (95% CI 0.38–0.72) vs abrupt discontinuation | High |
Key Findings on Anxiety Management Approaches
Both SSRIs and CBT Are Effective Acute Treatments, With Comparable Short-Term Outcomes
The accumulated evidence from over 375 RCTs supports both SSRIs and CBT as effective treatments for anxiety disorders in adults. The 2025 unified meta-analysis by Cuijpers and colleagues, published in JAMA Psychiatry, found that CBT produced effect sizes of 0.5–1.0 (Hedges’ g) compared with control conditions for GAD, panic disorder, and social anxiety — a range consistent with clinically meaningful improvement. Effect sizes were largest against waitlist controls (g > 0.94) and more modest against treatment as usual (g = 0.22–1.13), a pattern important for interpreting clinical applicability.
SSRIs demonstrate comparable acute efficacy. The CANMAT guidelines rate sertraline and escitalopram as preferred first-line agents for GAD based on their efficacy profiles and tolerability. Response rates for SSRIs in anxiety trials generally range from 50–60%, with remission rates of 30–40% — broadly similar to CBT response rates when adequately delivered. The 2025 meta-analysis of CBT across 30 years of trials (Hofmann et al.) found a stable mean effect size of g = 0.51 (95% CI 0.40–0.62) with no evidence of declining efficacy over time.
CBT Demonstrates a Durable Advantage After Treatment Ends
The most clinically significant distinction between CBT and pharmacotherapy is not acute efficacy but what happens after treatment stops. The 2023 JAMA Psychiatry network meta-analysis by Papola et al. evaluated 65 RCTs (n = 5048) for GAD specifically and found that only CBT — not pharmacotherapy, relaxation, or other psychotherapies — demonstrated sustained effectiveness at long-term follow-up after treatment withdrawal. This durability advantage is further supported by the Cuijpers 2023 depression meta-analysis, which found CBT was significantly more effective than pharmacotherapy at 6–12 month follow-up (g = 0.34, 95% CI 0.09–0.58).
Relapse data sharpen this contrast further. The Batelaan 2017 BMJ meta-analysis of 28 RCTs (n = 5233) found that approximately 36% of patients who responded to antidepressants for anxiety relapsed within one year of medication discontinuation, compared with 16% who continued treatment (OR 3.11, 95% CI 2.48–3.89). By comparison, the Lorimer 2021 meta-analysis found an overall relapse rate of only 14% following successful CBT for anxiety — suggesting that CBT equips patients with skills that persist after the active treatment phase ends.
The Papola 2023 network meta-analysis provides the most rigorous comparative data for GAD-specific psychotherapy. Among 65 RCTs, CBT and third-wave CBTs (acceptance and commitment therapy, mindfulness-based approaches) outperformed treatment as usual. When studies with high risk of bias were removed, only CBT and third-wave CBTs retained their superiority. Critically, only traditional CBT demonstrated effectiveness at long-term follow-up. Third-wave approaches are promising but have a smaller evidence base for GAD specifically. For pharmacotherapy, the CANMAT guidelines recommend sertraline, escitalopram, duloxetine, venlafaxine, and pregabalin as first-line options, with buspirone as a second-line alternative for patients intolerant of SSRI side effects.
For panic disorder, the AAFP clinical review (Penning 2022) summarises that both CBT and antidepressants are effective, with SSRIs producing remission in approximately 1 in 10 treated patients (NNT ≈ 10) over 2–6 months. CBT for panic disorder emphasises interoceptive exposure — deliberately inducing feared somatic sensations to decouple them from the fear response — which has been identified as the most beneficial component. The combination of CBT and pharmacotherapy is likely more effective than either alone for panic disorder, though the AAFP notes that head-to-head evidence is limited. An important clinical consideration: benzodiazepines used as needed may interfere with CBT’s exposure-based mechanisms by eliminating the anxiety needed for fear-extinction learning.
The 2025 Johnco meta-analysis (22 RCTs, n = 2549) provides the most current data on late-life anxiety treatment. CBT produced diagnostic remission in 54% of older adults versus 36% with pharmacotherapy, though direct head-to-head comparisons were sparse. Treatment response was 53% for CBT and 62% for pharmacotherapy (noting that response definitions varied widely across studies). CBT attrition was 19%, comparable to pharmacotherapy. CBT showed a 33% relapse rate — lower than the approximately 36% post-discontinuation relapse seen with pharmacotherapy in younger adult studies. These findings suggest that CBT may be particularly valuable in older populations where polypharmacy, fall risk from benzodiazepines, and drug interactions complicate pharmacological management.
Access to trained CBT therapists is the most frequently cited barrier to evidence-based psychological treatment in primary care. Therapist-supported internet-based CBT (iCBT) and app-based programmes offer a potential solution. The AAFP review notes limited but promising evidence that therapist-supported iCBT is effective, though comparisons with face-to-face delivery remain insufficient. A 2022 meta-analysis found that technology-delivered CBT produced comparable outcomes to active treatment controls, though effect sizes against passive controls were smaller than for face-to-face CBT. Critically, unsupervised digital self-help appears less effective than therapist-guided options. For primary care, the practical implication is that iCBT with some clinical oversight may serve as a viable bridge when face-to-face CBT is unavailable.
Combination Therapy Appears Superior but Evidence Remains Incomplete
Multiple guidelines and reviews endorse the combination of CBT with SSRI therapy as potentially more effective than either monotherapy. The AAFP primary care review states that combination treatment is “likely to be more effective than either treatment alone” for GAD and panic disorder. In the paediatric literature, the CAMS trial (Walkup 2008) provides the most robust direct comparison, finding that 80.7% of youth receiving combined CBT + sertraline showed significant improvement at 12 weeks, compared with 59.7% for CBT alone and 54.9% for sertraline alone.
However, a critical limitation is the paucity of well-powered adult RCTs conducted specifically in primary care comparing combination therapy against well-delivered monotherapy. Much of the evidence supporting combination is drawn from specialist settings, indirect comparisons across trials, and guideline consensus. The Cuijpers 2023 meta-analysis found that combined treatment was more effective than pharmacotherapy alone at both short-term (g = 0.51, 95% CI 0.19–0.84) and long-term follow-up (g = 0.32, 95% CI 0.09–0.55), but was not more effective than CBT alone — a finding that tilts the balance of evidence somewhat in favour of CBT as the core therapeutic modality.
Quality & Consistency of Evidence
What the Evidence Does Not Show
Despite a large overall evidence base, several gaps have direct implications for primary care decision-making.
Optimal sequencing of treatments. No RCT has determined whether starting with CBT and adding an SSRI for partial responders produces better long-term outcomes than the reverse sequence. Current practice typically defaults to SSRI initiation (due to prescriber access) with CBT referral as an adjunct — but whether this is the optimal sequence for sustained remission is unknown.
Primary care–specific combination data. Nearly all head-to-head comparisons of combination versus monotherapy come from specialist psychiatric settings. Whether the combination advantage persists with the brief, less intensive CBT models feasible in primary care (6–8 sessions versus 12–16) has not been adequately tested.
CBT-assisted SSRI deprescribing in anxiety. Only two small RCTs have examined CBT as a relapse prevention strategy during antidepressant discontinuation for anxiety disorders, and their results conflict. This contrasts with more robust evidence in depression. Given that millions of patients with anxiety take long-term antidepressants without reassessment, this gap is clinically urgent.
Differential response predictors. Clinicians lack validated tools to predict which patients with anxiety will respond preferentially to CBT versus SSRIs. Early neuroimaging research shows promise — heightened amygdala reactivity may predict better pharmacotherapy response, while greater prefrontal engagement may favour CBT — but no prediction model is ready for clinical use.
Practical Implications
Based on the current evidence, the following considerations may inform anxiety management decisions in primary care. These reflect synthesised findings and guideline positions — they are not directive prescribing guidance.
Evidence Grade & Bottom Line
Overall Evidence Grade: Strong (CBT and SSRIs as monotherapy) / Moderate (Combination therapy and sequencing)
Strong, consistent evidence from multiple large meta-analyses supports both CBT and SSRIs as effective first-line treatments for anxiety disorders in adults. The durability advantage of CBT is well-established. Evidence for combination therapy superiority is moderate — supported by guideline consensus and indirect meta-analytic evidence, but limited by insufficient head-to-head primary care trials.
The “strong” grade for both monotherapies means clinicians can be confident that either SSRIs or CBT will produce meaningful improvement in the majority of patients with GAD or panic disorder. The “moderate” grade for combination therapy and sequencing reflects that while combining treatments is likely beneficial for more severe cases, the specific evidence base for how and when to combine in primary care remains less certain and may evolve as new trials report.
- Both CBT and SSRIs are effective first-line treatments for anxiety disorders, with comparable acute efficacy (effect sizes of 0.5–1.0 versus control conditions).
- CBT provides a meaningful durability advantage: 14% relapse after CBT versus 36% after antidepressant discontinuation within one year.
- Combination therapy is likely superior for moderate-to-severe anxiety, but was not consistently more effective than CBT alone in meta-analytic data.
- Patient preference, symptom severity, access to CBT, comorbidity, and long-term treatment goals should all factor into the shared treatment selection decision.
- Key gaps remain in primary care–specific combination data, optimal sequencing strategies, and CBT-assisted antidepressant discontinuation for anxiety populations.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Cuijpers P, Harrer M, Papola D, et al. Cognitive behavior therapy for mental disorders in adults: a unified series of meta-analyses. JAMA Psychiatry. 2025;82(6):563–571. DOI: 10.1001/jamapsychiatry.2025.0482
- Papola D, Miguel C, Mazzaglia M, et al. Psychotherapies for generalized anxiety disorder in adults: a systematic review and network meta-analysis of randomized clinical trials. JAMA Psychiatry. 2024;81(3):250–259. DOI: 10.1001/jamapsychiatry.2023.3971
- Hofmann SG, et al. Effect sizes of randomized-controlled studies of cognitive behavioral therapy for anxiety disorders over the past 30 years. Clin Psychol Rev. 2025;116:102504. DOI: 10.1016/j.cpr.2025.102504
- Cuijpers P, Quero S, Noma H, et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 2023;22(1):105–115. DOI: 10.1002/wps.21069
- Batelaan NM, Bosman RC, Muntingh A, Scholten WD, ter Harmsel J, van Balkom AJLM. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017;358:j3927. DOI: 10.1136/bmj.j3927
- Lorimer B, Kellett S, Nye A, Delgadillo J. A meta-analysis of relapse rates in cognitive-behavioral therapy for anxiety disorders. J Anxiety Disord. 2021;80:102385. DOI: 10.1016/j.janxdis.2021.102385
- Johnco CJ, Dickson S, Seaton A. A systematic review and meta-analysis of diagnostic remission, treatment response, attrition and relapse following cognitive behavior therapy (CBT), other psychological therapies and pharmacological treatments for anxiety disorders in older adults. Am J Geriatr Psychiatry. 2025. DOI: 10.1016/j.jagp.2025.06.010
- Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1. DOI: 10.1186/1471-244X-14-S1-S1
- Penning S, Field J. Generalized anxiety disorder and panic disorder in adults. Am Fam Physician. 2022;106(2):157–164. Available at: aafp.org
- Scholten WD, Batelaan NM, van Oppen P, et al. The efficacy of a group CBT relapse prevention program for remitted anxiety disorder patients who discontinue antidepressant medication: a randomized controlled trial. Psychother Psychosom. 2018;87(4):240–242. DOI: 10.1159/000489942
- van Dis EAM, van Veen SC, Hagenaars MA, et al. Psychological interventions to prevent relapse in anxiety and depression: a systematic review and meta-analysis. PLoS One. 2022;17(8):e0272200. DOI: 10.1371/journal.pone.0272200
- Brouwer ME, Williams AD, Kennis M, et al. Comparison of antidepressant deprescribing strategies in individuals with clinically remitted depression: a systematic review and network meta-analysis. Lancet Psychiatry. 2026. DOI: 10.1016/S2215-0366(25)00330-X